Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The End Of The FDA Approvals Boom? Fewer Applications Are A COVID-19 Consequence

Jun 23 2020

• By Bridget Silverman

Down arrow on pavement

Related Content

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Jan 25 2020

US FDA Not Missing Assessment Goals, But Guidance Reminds That It’s Possible

Jun 01 2020

Keeping Track Of Submissions: Myovant’s First Relugolix NDA; Merck Resubmits Longer Keytruda Dosing; Biogen Adjusts Aducanumab Rolling Target

Apr 28 2020

US FDA May Start To Miss User Fee Deadlines

Apr 17 2020

Related Companies

Biogen, Inc.

Genetix Biotherapeutics

PTC Therapeutics, Inc.

Clearside Biomedical, Inc.

Additional Topics

United States Drug Review Approvals Regulation BioPharmaceutical

More from Product Reviews

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window